Treace Medical Concepts Logo
US89455T1097
A3CM04
TMCI

Treace Medical Concepts

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 5,92 (-74,13%). A mediana é € 5,92 (-74,13%).

Comprar
  3
Manter
  5
Vender
  1

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Treace Medical beats Q2 forecasts; shares jump about 24% premarket

    Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » Mais em de.investing.com


  • Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly

    Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » Mais em de.investing.com


  • Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand

    Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » Mais em de.investing.com


  • Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making

    Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » Mais em de.investing.com


  • Treace Medical Concepts beats Q2 forecasts and shares rise after hours

    Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Treace Medical Concepts registou receitas de € 42,6 mi e um ganho líquido de -€ 11,09 mi
(EUR) setembro de 2026
YoY
Receitas 42,6 mi 0,44%
Ganho bruto 33,86 mi 0,07%
Ganho líquido -11,09 mi 20,07%
EBITDA -9,7 mi 6,52%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 264,93 mi
Número de ações
65,56 mi
Máximo/mínimo de 52 semanas
€ 4,95 - € 1,06
Dividendos Não
Beta
1,56
PER (PE Ratio)
-5,16
PEG (PEG Ratio)
0,49
P/VC (PB Ratio)
4,72
P/V (PS Ratio)
1,43

Perfil da empresa

A Treace Medical Concepts, Inc., uma empresa de dispositivos médicos ortopédicos, dedica-se à conceção, fabrico e comercialização de dispositivos médicos destinados a cirurgiões do pé e do tornozelo nos Estados Unidos. Oferece o procedimento Lapiplasty, que permite aos cirurgiões podiátricos tratar as três dimensões do joanete, proporcionando aos doentes uma melhoria estética e médica. A empresa disponibiliza também o sistema de precisão Lapiplasty Mini-Incision. Além disso, oferece produtos para procedimentos cirúrgicos auxiliares, incluindo osteotomias de Akin, osteotomias de Weil, estabilização intercuneiforme, artrodeses da articulação tarsometatársica lateral e colheita de enxerto ósseo autólogo, bem como para a artrodese MTP. A Treace Medical Concepts, Inc. foi fundada em 2013 e tem sede em Ponte Vedra Beach, Florida.

Nome
Treace Medical Concepts
CEO
John T. Treace
Sede Ponte Vedra, fl
EUA
Site
Setor
Bens de consumo não essenciais
Indústria
Bens de consumo duradouros
Entrada em bolsa
23/04/2021
Colaboradores 450

Símbolos de ticker

Bolsa Símbolo
NASDAQ
TMCI
🍪

Parqet  utiliza cookies. Saber mais